Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR T – BioPharma-Reporter.com
BioPharma-Reporter.com |
Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR T
BioPharma-Reporter.com Gilead will also add a chimeric antigen receptor (CAR) T-cell manufacturing facility in El Segunda, California which opened in June last year and has the capacity to produce volumes of the autologous therapy for up to 4,000-5,000 patients per year. Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapy Gilead's Plan? Cash In on CAR–T Gilead just handed a revolutionary kind of cancer treatment a $12 billion endorsement |
